Dianthus Therapeutics Inc [DNTH] stock prices are down -0.13% to $23.83 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The DNTH shares have gain 14.73% over the last week, with a monthly amount drifted -14.13%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dianthus Therapeutics Inc [NASDAQ: DNTH] stock has seen the most recent analyst activity on October 03, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $48. Previously, Robert W. Baird started tracking the stock with Outperform rating on July 26, 2024, and set its price target to $58. On June 27, 2024, Cantor Fitzgerald initiated with a Overweight rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 16, 2024. Stifel initiated its recommendation with a Buy and recommended $44 as its price target on February 15, 2024. Jefferies started tracking with a Buy rating for this stock on December 26, 2023, and assigned it a price target of $22. In a note dated November 22, 2023, Wedbush initiated an Outperform rating and provided a target price of $23 on this stock.
The stock price of Dianthus Therapeutics Inc [DNTH] has been fluctuating between $6.58 and $33.77 over the past year. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $23.83 at the most recent close of the market. An investor can expect a potential return of 116.11% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
The Dianthus Therapeutics Inc [NASDAQ:DNTH] reported sales of 5.37M for trailing twelve months, representing a surge of 135.06%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -15.45%, Pretax Profit Margin comes in at -12.5%, and Net Profit Margin reading is -12.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.22 and Total Capital is -0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.27 points at the first support level, and at 22.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.19, and for the 2nd resistance point, it is at 24.55.
Ratios To Look Out For
It’s worth pointing out that Dianthus Therapeutics Inc [NASDAQ:DNTH]’s Current Ratio is 18.30. On the other hand, the Quick Ratio is 18.30, and the Cash Ratio is 2.14. Considering the valuation of this stock, the price to sales ratio is 131.34, the price to book ratio is 2.07.